Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Orenitram,remodulin
Synonyms :
treprostinil
Class :
Pulmonary hypertension, prostacyclin analogues
Brand Name :
Orenitram,remodulin
Synonyms :
treprostinil
Class :
Pulmonary hypertension, prostacyclin analogues
Dosage Forms & StrengthsÂ
Extended-release tablets:Â
0.125mg,0.25mg,1mg,2.5mg,5mgÂ
Injectable solutionÂ
1mg/mlÂ
2.5mg/mlÂ
5mg/mlÂ
10mg/mlÂ
Pulmonary Arterial HypertensionÂ
Extended-release tablets:
Initial dose: 0.25 mg orally every 12 hours or 0.125 mg every 8 hours
Maintenance dose: Increase 0.125 mg 3 times a day every 3 to 4 days or increase 0.25 or 0.5 mg twice a day
Inhalation:
Initial dose: 4 times a day, three breaths (18 mcg) each treatment session; if not tolerated, reduce to 1 or 2 breaths; increase to 3 breaths as tolerated
Maintenance dose: Once the intended dose of 9 breathes (54 mcg) per treatment session is attained, increase by an additional three breaths at about 1-to-2-week intervals as tolerated
Maximum dose: 4 times daily treatment sessions of 9 breaths (54 mcg)
Injectable
Initial dose: Continuous subcutaneous or intravenous infusion of 1.25 ng/kg/min; if this dosage is intolerable, lower it to 0.625 ng/kg/min
Maintenance dose: During the first four weeks, increase the infusion rate by 1.25 ng/kg/min each week. Then, for the remaining four weeks, increase the rate by 2.5 ng/kg/min each week
Dosage Forms & StrengthsÂ
Injectable solutionÂ
1mg/mlÂ
2.5mg/mlÂ
5mg/mlÂ
10mg/mlÂ
Pulmonary Arterial HypertensionÂ
<18 years: Safety and efficacy not established
Injectable (> 16 years)
Initial dose: 1.25 ng/kg/min subcutaneous/Intravenous infusion
Do not increase more than 1.25 ng/kg/min every week for four weeks
Oral tablet
Initial dose: 0.25mg orally, twice a day. Increase up to 0.5mg twice daily every 3-4 days
Maximum dose: 3.4mg twice a day
Refer adult dosingÂ
gilteritinib may enhance the QTc-prolonging effect of QT-prolonging Agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect
may enhance the serum concentration of CYP2C8 inhibitors
may increase the QTc prolonging effect
may have an increased QTc-prolonging effect when combined with amisulpride (oral)
may increase the QTc prolonging effect of QT-prolonging agents
may have an increased QTc-prolonging effect when combined with amiodarone
may have an increased QTc-prolonging effect when combined with delamanid
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
encorafenib: they may increase the QTc-prolonging effect of QTc-prolonging agents
etelcalcetide: they may increase the QTc-prolonging effect of QTc-prolonging agents
flecainide: they may increase the QTc-prolonging effect of QTc-prolonging Agents
fluconazole: they may increase the QTc-prolonging effect of QTc-prolonging agents
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
sunitinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
dapagliflozin: it may increase the risk or severity of QTc prolongation
may enhance the effects of the other by pharmacodynamic synergism
it may enhance the QTc-prolonging effect of terfenadine
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with pazopanib
may have an increased vasodilatory effect when combined with vasodilators
may have an increased vasodilatory effect when combined with vasodilators
may have an increased hypotensive effect when combined with riociguat
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
clarithromycin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
levoketoconazole: they may increase the QTc-prolonging effect of QTc-prolonging Agents
probucol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
sparfloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
the QTc-prolonging effect of citalopram can be increased with QT-prolonging agents
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may increase the levels of each other by decreasing metabolism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may increase the effect of each other through anticoagulation
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the concentration of serum when combined with treprostinil
may enhance the concentration of serum when combined with treprostinil
may enhance the concentration of serum when combined with treprostinil
may enhance the concentration of serum when combined with treprostinil
may have an increased QTc-prolonged effect when combined with chloroquine
may have an increased QTc-prolonged effect when combined with chloroquine
may increase the QTc prolonging effect of QTc prolonging agents
may have an increased QTc-prolonging effect when combined with haloperidol
may increase the vasodilatory effect
may increase the vasodilatory effect
may increase the vasodilatory effect
may increase the vasodilatory effect
may increase the vasodilatory effect
may have an increased QTc-prolonging effect when combined with chloroquine
may have an increased QTc-prolonging effect when combined with gadobenate dimeglumine
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
fingolimod: they may increase the QTc-prolonging effect of QT-prolonging Agents
the : QTc-prolonging effect of hydroxyzine can be increased with QT-prolonging agents
cetirizine: it may increase the risk or severity of QTc prolongation
atropine: it may increase the risk or severity of QTc prolongation
benorilate: it may increase the risk or severity of QTc prolongation agents
cabergoline: it may increase the risk or severity of QTc prolongation agents
canagliflozin: it may increase the risk or severity of QTc prolongation agents
candesartan cilexetil: it may increase the risk or severity of QTc prolongation agents
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of domperidone
Frequency defined:Â Â
>10%Â
NauseaÂ
VasodilationÂ
Reaction at the infusion siteÂ
HeadacheÂ
RashÂ
DiarrheaÂ
1-10%Â
EdemaÂ
HypotensionÂ
DizzinessÂ
PruritisÂ
Frequency not definedÂ
CellulitisÂ
AngioedemaÂ
Bone painÂ
RestlessnessÂ
HemoptysisÂ
Post-marketing reportsÂ
VomitingÂ
ArthralgiaÂ
Pain extremityÂ
DyspepsiaÂ
MyalgiaÂ
Gastrointestinal effectsÂ
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Patient information leafletÂ
Generic Name: TreprostinilÂ
Pronounced: tre·pros·tinilÂ
Why do we use Treprostinil?Â
It is a prostacyclin vasodilator used to treat pulmonary arterial hypertension by relieving exercise-related symptoms.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
